Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Chief Financial Officer | December 19, 2024 | December 23, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date December 19, 2024 · Filed December 23, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 377,867 |
Ending reported balance
After 2024-12-19 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-12-19 · Grant · Acquired 120,700 · Balance 380,328 F1: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. Row 2 · 2024-12-19 · Tax withholding · Disposed 2,461 · Balance 377,867 F2: Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the Reporting Person. |
| Emp. Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.39 · Expires 2034-12-19 | Direct | 250,100 |
Reported balance
After 2024-12-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-12-19 · Grant · Acquired 250,100 · Balance 250,100 F3: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.
F2: Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the Reporting Person.
F3: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 19, 2024 Filed Dec 23, 2024 21:11 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 250,100 | $0.00 Strike: $7.39 | $0.00 |
DisclosureSEC source: 0001127602-24-029965 · form4.xml · derivative · entry 3 Doyle Anthony · CIK 0001808688 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,100 Underlying: Common Stock · 250,100 shares Expires 2034-12-19 F3 · derivative.exercise_date: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 19, 2024 Filed Dec 23, 2024 21:11 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 2,461 | $7.39 | $18,186.79 |
DisclosureSEC source: 0001127602-24-029965 · form4.xml · nonDerivative · entry 2 Doyle Anthony · CIK 0001808688 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 377,867 F2 · shares: Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the Reporting Person. Read SEC document |
| December 19, 2024 Filed Dec 23, 2024 21:11 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 120,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-029965 · form4.xml · nonDerivative · entry 1 Doyle Anthony · CIK 0001808688 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380,328 F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 14, 2024 Filed Dec 17, 2024 21:06 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 7,890 | $7.53 | $59,411.70 |
DisclosureSEC source: 0001127602-24-029573 · form4.xml · nonDerivative · entry 1 Doyle Anthony · CIK 0001808688 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 259,628 F1 · shares: Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the Reporting Person. Read SEC document |
| May 14, 2024 Filed May 15, 2024 11:19 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | PurchaseCommon Stock | 36,300 | $5.57 | $202,191.00 |
DisclosureSEC source: 0001127602-24-015373 · form4.xml · nonDerivative · entry 1 Doyle Anthony · CIK 0001808688 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 266,744 Read SEC document |
| December 19, 2023 Filed Dec 20, 2023 21:35 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 2,482 | $6.05 | $15,016.10 |
DisclosureSEC source: 0001127602-23-030181 · form4.xml · nonDerivative · entry 1 Doyle Anthony · CIK 0001808688 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,444 F1 · shares: Represents shares withheld by the issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the reporting person. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 21:37 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 158,500 | $0.00 Strike: $6.43 | $0.00 |
DisclosureSEC source: 0001127602-23-029831 · form4.xml · derivative · entry 3 Doyle Anthony · CIK 0001808688 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,500 Underlying: Common Stock · 158,500 shares Expires 2033-12-14 F3 · derivative.exercise_date: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 21:37 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 5,475 | $6.43 | $35,204.25 |
DisclosureSEC source: 0001127602-23-029831 · form4.xml · nonDerivative · entry 2 Doyle Anthony · CIK 0001808688 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 229,926 F2 · shares: Represents shares withheld by the issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the reporting person. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 21:37 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 34,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-029831 · form4.xml · nonDerivative · entry 1 Doyle Anthony · CIK 0001808688 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,401 F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:32 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 158,500 | $0.00 Strike: $10.63 | $0.00 |
DisclosureSEC source: 0001127602-22-028074 · form4.xml · derivative · entry 2 Doyle Anthony · CIK 0001808688 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,500 Underlying: Common Stock · 158,500 shares Expires 2032-12-19 F2 · derivative.exercise_date: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:32 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 34,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-028074 · form4.xml · nonDerivative · entry 1 Doyle Anthony · CIK 0001808688 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,966 F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 15, 2022 Filed Dec 19, 2022 21:55 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 5,700 | $10.90 | $62,130.00 |
DisclosureSEC source: 0001127602-22-027883 · form4.xml · nonDerivative · entry 1 Doyle Anthony · CIK 0001808688 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,966 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2022 to cover tax withholding obligations in connection with the vesting of 18,750 Restricted Stock Units. The sale occurred automatically to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.50 to $11.35. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 21:59 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 164,000 | $0.00 Strike: $11.43 | $0.00 |
DisclosureSEC source: 0001127602-21-031121 · form4.xml · derivative · entry 2 Doyle Anthony · CIK 0001808688 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,000 Underlying: Common Stock · 164,000 shares Expires 2031-12-14 F2 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 21:59 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 115,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-031121 · form4.xml · nonDerivative · entry 1 Doyle Anthony · CIK 0001808688 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,719 F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 14, 2021 Filed Jan 13, 2022 21:40 UTC Amendment | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-001456 · form4a.xml · nonDerivative · entry 1 Doyle Anthony · CIK 0001808688 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,719 F1 · shares: The number of restricted stock units awarded to the reporting person on December 14, 2021 was overstated in the original Form 4 due to an administrative error. This amendment corrects the error and reflects the corrected amount of restricted stock units awarded to the reporting person on such date. Read SEC document |
| November 23, 2021 Filed Nov 24, 2021 23:35 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | PurchaseCommon Stock | 35,258 | $12.48 | $440,019.84 |
DisclosureSEC source: 0001171843-21-008176 · ownership.xml · nonDerivative · entry 1 Doyle Anthony · CIK 0001808688 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,719 Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:23 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 332,500 | $0.00 Strike: $8.31 | $0.00 |
DisclosureSEC source: 0001127602-20-031782 · form4.xml · derivative · entry 1 Doyle Anthony · CIK 0001808688 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,500 Underlying: Common Stock · 332,500 shares Expires 2030-12-15 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| August 11, 2020 Filed Aug 12, 2020 20:31 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | PurchaseCommon Stock | 54,000 | $4.08 | $220,320.00 |
DisclosureSEC source: 0001127602-20-023449 · form4.xml · nonDerivative · entry 1 Doyle Anthony · CIK 0001808688 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,000 Read SEC document |
| April 30, 2020 Filed May 4, 2020 20:08 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 600,000 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0001127602-20-015179 · form4.xml · derivative · entry 1 Doyle Anthony · CIK 0001808688 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2020-04-30 F1 · shares: Initial Employee Option Grant, 200,000 of which become exercisable on the first anniversary of the grant date or upon termination if, within the first year of his employment, Mr. Doyle is impacted by a reduction in force at the Company, and the remainder of which will vest in three equal installments on the second, third and fourth anniversaries of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.